ホーム>>Biochemical Assay Reagents>>Gelucire 14/44

Gelucire 14/44

カタログ番号GC34591

Gelucire 14/44 は、肺送達によるインスリンやカルシトニンなどの吸収性の低い薬物の吸収を改善するための潜在的かつ安全な吸収促進剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Gelucire 14/44 化学構造

Cas No.: 121548-04-7

サイズ 価格 在庫数 個数
25g
$45.00
在庫あり
50g
$72.00
在庫あり
100g
$117.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Gelucire 44/14 is a potential and safe absorption enhancer for improving the absorption of poorly absorbable drugs including insulin and calcitonin by pulmonary delivery.

Gelucire 44/14 is a potential and safe absorption enhancer for improving the absorption of poorly absorbable drugs including insulin and calcitonin by pulmonary delivery. It is found that pulmonary absorptions of FD4, FD10 and FD70 are enhanced in different degree by Gelucire 44/14 in a concentration-dependent manner, and the maximal absorption-enhancing effect is obtained when the concentration of Gelucire 44/14 reaches to 2.0% (w/v). It is also found that the absorption enhancing ability of Gelucire 44/14 is correlated with the molecular weight of model drugs, and the highest absorption enhancement ratio of Gelucire 44/14 is observed when the molecular weight of model drugs reaches to nearly 10000 Da[1].

[1]. Zhang H, et al. Improvement of pulmonary absorptions of poorly absorbable drugs using Gelucire 44/14 as an absorption enhancer. J Pharm Pharmacol. 2014 Oct;66(10):1410-20.

レビュー

Review for Gelucire 14/44

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gelucire 14/44

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.